Adverum Biotechnologies (ADVM) Competitors $2.59 -0.20 (-7.17%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.59 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. ZYBT, ESPR, DBVT, MDWD, YMAB, TIL, SLRN, IMAB, DSGN, and SCPHShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Zhengye Biotechnology (ZYBT), Esperion Therapeutics (ESPR), DBV Technologies (DBVT), MediWound (MDWD), Y-mAbs Therapeutics (YMAB), Instil Bio (TIL), Acelyrin (SLRN), I-Mab (IMAB), Design Therapeutics (DSGN), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Zhengye Biotechnology Esperion Therapeutics DBV Technologies MediWound Y-mAbs Therapeutics Instil Bio Acelyrin I-Mab Design Therapeutics scPharmaceuticals Zhengye Biotechnology (NASDAQ:ZYBT) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Do insiders & institutionals believe in ZYBT or ADVM? 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 6.0% of Adverum Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor ZYBT or ADVM? In the previous week, Adverum Biotechnologies had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Adverum Biotechnologies and 3 mentions for Zhengye Biotechnology. Adverum Biotechnologies' average media sentiment score of 0.63 beat Zhengye Biotechnology's score of 0.62 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adverum Biotechnologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in ZYBT or ADVM? Adverum Biotechnologies received 373 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformZhengye BiotechnologyN/AN/AAdverum BiotechnologiesOutperform Votes37360.26% Underperform Votes24639.74% Do analysts rate ZYBT or ADVM? Adverum Biotechnologies has a consensus price target of $26.40, suggesting a potential upside of 919.31%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is ZYBT or ADVM more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Adverum Biotechnologies N/A -65.14%-40.52% Which has stronger earnings & valuation, ZYBT or ADVM? Zhengye Biotechnology has higher revenue and earnings than Adverum Biotechnologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$189.75M1.73N/AN/AN/AAdverum Biotechnologies$1M54.11-$117.17M-$6.40-0.40 SummaryAdverum Biotechnologies beats Zhengye Biotechnology on 9 of the 12 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.11M$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.4333.3227.1120.06Price / Sales54.11469.84409.88157.10Price / CashN/A168.6838.2534.64Price / Book0.313.457.064.70Net Income-$117.17M-$72.35M$3.23B$247.88M7 Day Performance7.02%6.23%2.88%2.66%1 Month Performance-4.43%16.53%9.04%6.40%1 Year Performance-67.09%-16.90%31.40%14.07% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.001 of 5 stars$2.59-7.2%$26.40+919.3%-64.6%$54.11M$1M-0.43190Positive NewsShort Interest ↑ZYBTZhengye BiotechnologyN/A$5.16-12.7%N/AN/A$243.38M$189.75M0.00278Gap UpESPREsperion Therapeutics4.1016 of 5 stars$1.20-1.6%$6.25+420.8%-58.3%$237.84M$259.57M-1.88200Options VolumeAnalyst RevisionDBVTDBV Technologies3.4401 of 5 stars$8.68-4.9%$14.75+69.9%+72.7%$237.75M$15.73M-1.9380News CoverageMDWDMediWound1.7844 of 5 stars$21.46-0.6%$31.80+48.2%+26.0%$231.94M$19.21M-7.4080YMABY-mAbs Therapeutics3.7663 of 5 stars$5.08-3.6%$15.60+207.1%-59.0%$230.04M$88.66M-9.41150Positive NewsAnalyst RevisionTILInstil Bio2.6702 of 5 stars$35.07+6.6%$119.00+239.3%+237.3%$230.02MN/A-3.03410Short Interest ↑High Trading VolumeSLRNAcelyrin2.9724 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135Positive NewsIMABI-Mab3.2077 of 5 stars$2.80+14.3%$5.50+96.4%+33.9%$228.65M$3.27M0.00380High Trading VolumeDSGNDesign Therapeutics0.7089 of 5 stars$3.91-2.5%$4.00+2.3%-3.2%$227.64MN/A-4.6040Positive NewsGap UpSCPHscPharmaceuticals4.4331 of 5 stars$4.25+1.2%$14.00+229.4%-0.7%$224.37M$41.98M-2.2430Positive News Related Companies and Tools Related Companies ZYBT Alternatives ESPR Alternatives DBVT Alternatives MDWD Alternatives YMAB Alternatives TIL Alternatives SLRN Alternatives IMAB Alternatives DSGN Alternatives SCPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADVM Stock Free ADVM Stock Alerts